Key Takeaways
Medicare skin substitute billing is facing heightened scrutiny as spending, utilization and enforcement activity continue to rise. Providers should prepare for more front-end claim review by strengthening medical necessity documentation, monitoring billing patterns and ensuring product use is based on clinical need.
Skin substitutes, also known as cellular and tissue-based products or CTPs, have rapidly become one of Medicare’s highest risk billing categories. While these products remain an important tool in wound care, the sharp rise in spending and utilization has triggered intense regulatory scrutiny. What began as a promising treatment category is now under close review as regulators question whether financial incentives have, in some cases, influenced clinical decision making.
Why Regulators Are Focused on CTPs
According to a September 2025 report from the HHS Office of Inspector General, Medicare Part B spending on skin substitutes increased from under $400 million in 2022 to more than $10 billion in 2024. Utilization also rose sharply, and traditional Medicare paid substantially more than Medicare Advantage for similar patient populations. Regulators view that disparity as a sign that payment incentives, rather than patient need, may be driving some utilization. The OIG concluded that skin substitute billing is particularly vulnerable to questionable billing practices and fraud schemes.
A Coordinated Federal Crackdown
This spending trajectory prompted a coordinated response from CMS, the OIG and the Department of Justice. False Claims Act enforcement reached record levels in 2025, supported by new fraud detection infrastructure and advanced analytics that review millions of claims each day.
Skin substitutes are now a priority enforcement area, with regulators pursuing both civil and criminal cases involving providers, billing companies, distributors and technology platforms.
Common Billing Red Flags
Regulatory actions and audits have consistently identified several high-risk billing patterns, including:
- First-visit graft application without prior conservative treatment. Using skin substitutes at a patient’s initial wound care visit, before documented conservative therapies have been attempted, is a primary red flag.
- Repeated applications without evidence of wound improvement. Continuing CTP applications without documented wound progression, including photographs, measurements and clinical notes showing healing, suggests that utilization may not be medically justified.
- Excessive graft quantities or sizes. Applying products in quantities or sizes that are not supported by wound dimensions is a marker of potential overutilization. In the Apex scheme, untrained sales representatives ordered only the largest graft sizes available regardless of wound size, and nurse practitioners were instructed to apply whatever was ordered, resulting in large grafts on small wounds, multiple grafts on single wounds and grafts on non-existent wounds.
- Disproportionate use in home-based or hospice settings. The OIG found that Medicare spending on skin substitutes for home care patients was four times higher than for patients treated in office settings. The Apex prosecution specifically alleged that hospice was targeted because “that’s where the most money was.”
- Use for non-approved conditions or experimental products. As part of the June 2025 takedown, one individual agreed to pay over $1.1 million to resolve allegations of billing Medicare for FlowerAmnioFlo, an injectable amniotic product considered experimental.
Recent prosecutions allege that, in some cases, sales representatives rather than clinicians drove graft selection, with products chosen based on reimbursement potential rather than clinical need.
Enforcement Consequences Are Severe
Between 2023 and 2025, federal enforcement actions resulted in:
- False Claims Act settlements totaling hundreds of millions of dollars
- Long term exclusions from federal health care programs
- Criminal convictions with prison sentences exceeding a decade
- Significant restitution orders and asset forfeiture
Notably, the Department of Justice has pursued cases without whistleblowers and has identified electronic health record systems and utilization software as enforcement targets when technology is used to drive inappropriate billing.
2026 Payment Reform Changes the Risk Landscape
CMS has paired enforcement with a fundamental payment overhaul. Effective January 1, 2026, most skin substitutes are reimbursed under a single national flat rate, replacing product-specific reimbursement based on average sales price. This change is designed to eliminate financial incentives tied to higher cost products.
At the same time, CMS has shifted from post-payment audits to front-end claim scrutiny. Documentation deficiencies may now result in immediate denials or payment holds rather than delayed recoupments years later.
CMS has also launched the Wasteful and Inappropriate Service Reduction program in select states. This model applies prior authorization-style oversight to skin substitutes using algorithms, artificial intelligence tools and clinical review. WiSeR is widely viewed as a framework for future Medicare oversight if utilization does not stabilize.
The Bottom Line
Skin substitute billing has entered a high-risk compliance era. Regulators have made their expectations clear. Providers must demonstrate prudent use, robust medical necessity documentation and compliance controls capable of withstanding pre-payment review.
While skin substitutes remain an important wound care tool, organizations must now operate under the assumption that claims will be reviewed before payment. The window for reactive compliance has closed.
Real-World Enforcement Examples to Consider:
Recent enforcement actions demonstrate that DOJ, OIG and CMS are pursuing both criminal and civil enforcement across the full spectrum of improper skin substitute billing. The table below summarizes representative cases:
- 2023, DOJ, Central District of California: A Beverly Hills plastic surgeon, along with related medical practices and a billing company, falsified place-of-service codes on skin graft claims to maximize Medicare and Medicaid reimbursement and failed to properly dispose of unused portions of single-use skin substitute products, instead reusing them on other patients, resulting in thousands of instances of double-billing
$23.9 million FCA settlement (Medicare and Medicaid; California received approximately $497,619 for its Medicaid share). The surgeon and associated medical group received a 15-year federal health program exclusion; the surgeon’s son received a 3-year exclusion.
Takeaway: Place-of-service manipulation and reuse of single-use graft materials constitute serious FCA violations that can end a practice’s ability to participate in federal programs.
- 2024 to 2025, DOJ, District of Arizona (Apex Medical): Owners of Arizona wound graft companies orchestrated a $1.2 billion kickback fueled scheme from November 2022 through May 2024. The wholesale graft distributor paid over $279 million in kickbacks to one owner and $130 million to the other owner’s company.
Medically untrained sales representatives were paid to find elderly Medicare beneficiaries, particularly those in hospice, and order the largest possible amniotic allografts regardless of wound size.
Nurse practitioners were instructed to suspend their medical judgment and apply whatever was ordered. Grafts were applied to small wounds, wounds that did not exist, and to terminally ill patients who died within days or on the same day of application.
Over an 18-month period, $1,212,005,778 in false claims were submitted, of which $614,945,420 was paid by federal and commercial programs.
-
- Criminal: Both owners pleaded guilty to conspiracy to commit health care fraud and wire fraud. One was sentenced to 15.5 years and the other to 14 years in prison. Combined restitution orders exceeded $1.2 billion. Assets seized included $97 million from 28 bank accounts, three life insurance annuities exceeding $21 million, four luxury vehicles purchased for over $988,000, $367,150 in cash, and over $348,000 in gold and silver.
Civil: $309 million FCA settlement ($279,912,916 from the owner and Apex Medical LLC; $30 million from the co-owner), resolving qui tam allegations that remain under seal as the investigation of other parties continues.
Takeaway: This case, described by DOJ as the “first prosecution of its kind,” demonstrates that extreme kickback fueled CTP schemes targeting vulnerable patients will result in decades long prison sentences and asset forfeiture at an unprecedented scale.
- 2025, DOJ, Southern District of Florida (Vohra): The United States filed an original FCA complaint (without a whistleblower relator) against Physicians Management LLC (Vohra), one of the nation’s largest bedside wound care providers for nursing home and SNF patients. Allegations included unnecessary surgical debridements, upcoding to higher-reimbursed procedures driven by corporate revenue quotas, and pre-programmed EHR and billing software that restricted physicians’ clinical decisions and ensured the system always billed for higher-reimbursed products. The EHR’s automated features allegedly exaggerated wound severity and minimized clinical documentation.
$45 million FCA settlement and a five-year Corporate Integrity Agreement with HHS-OIG. The CIA includes a novel health information technology (HIT) oversight provision requiring an IRO to assess all EHR systems and software used for treatment or payment.
-
- The company’s chief technology officer and EHR directors must provide OIG with certifications of EHR functionality, implementing a key DOJ HHS FCA Working Group priority targeting manipulation of Electronic Health Records systems to drive inappropriate utilization.
Takeaway: The DOJ is willing to pursue skin substitute fraud cases on its own initiative (without a relator), and EHR systems are now a direct target of enforcement and compliance monitoring. Revenue-target-driven upcoding will trigger both financial penalties and ongoing federal oversight of technology infrastructure.
- 2025, DOJ, Southern District of Texas: A Houston podiatrist and business partner were indicted on 14 counts of healthcare fraud for billing Medicare over $90 million (of which more than $45 million was reimbursed) for applying skin substitute grafts to patients who had no actual wounds.
They allegedly misrepresented CTP treatments as “stem cell” therapies for body pain, swelling, and as an “energy booster.” They fabricated wound diagnoses and created false follow-up reports purporting to show wound healing. After federal agents searched their business, they are accused of pressuring patients into writing false statements to cover up the fraud.
-
- Profits were spent on cryptocurrency, luxury vehicles, jewelry, and private jets. The scheme ran from 2022 to 2024, and the business was warned by Medicare about its billing procedures in February 2023, but continued.
Criminal case pending (both defendants pleaded not guilty). If convicted, they face up to decades in prison. Takeaway: Fabricating wound diagnoses to justify CTP applications, and obstructing investigations after they commence, represents the most egregious tier of fraud and draws aggressive criminal prosecution.
These cases illustrate a critical point: enforcement is no longer limited to fringe actors. It now reaches mainstream providers, billing vendors and technology platforms.
Beyond the cases above, the June 2025 national takedown yielded additional skin-substitute-specific enforcement actions, including charges against nurse practitioners who applied amniotic grafts without coordination with treating physicians, to superficial wounds that did not need treatment and in product sizes that were excessively larger than the wound.
One nurse practitioner was charged for applying grafts at the direction of medically untrained sales representatives without exercising independent medical judgment. The fact that nurse practitioners, rather than physicians, appear in many of these indictments suggests they may be disproportionately vulnerable to arrangements in which distributors or sales representatives dictate CTP utilization through improper financial incentives.
Our Windham Brannon team is here to help. If you have questions or need support, please reach out to Lori Baker or your Windham Brannon advisor today.
Frequently Asked Questions
- Why is Medicare focused on skin substitute billing? Spending and utilization have increased sharply, raising concerns that some claims may be driven by payment incentives rather than patient need.
- What documentation should providers maintain? Providers should document wound measurements, photographs, conservative treatment history, clinical rationale and evidence of healing progress.
- What billing patterns raise compliance concerns? Common red flags include first-visit graft application, repeated use without improvement, excessive graft size and use in settings with limited medical necessity support.
- How can organizations reduce risk? Regular claim reviews, clear clinical protocols, vendor oversight and staff training can help support compliant skin substitute use.
